Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 5Sarcoma, Ewing 1Rhabdomyosarcoma 1Rhabdoid Tumor 1Osteosarcoma 1Medulloblastoma 1Glioma 1Glioblastoma 1Ganglioneuroblastoma 1Ependymoma 1Diffuse Intrinsic Pontine Glioma 1Brain Neoplasms 1

Interventions

Ifosfamide 5Temozolomide 4surufatinib 2irinotecan sucrosofate 2Vincristine 2Radiotherapy 2Nivolumab 2Irinotecan 2Gemcitabine 2Etoposide 2Doxorubicin 2vactosertib 1temsirolimus 1talazoparib 1silmitasertib 1selinexor 1regorafenib 1pepinemab 1pegylated granulocyte colony-stimulating factor 1pegfilgrastim 1pazopanib 1olaparib 1lutetium Lu 177 dotatate 1liposomal doxorubicin 1lenvatinib 1etoposide phosphate 1endostar protein 1dostarlimab 1dinutuximab 1copanlisib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Osteosarcoma × dinutuximab × Clear all
NCT04238819 2026-03-02

A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma

Eli Lilly and Company

Phase 1/2 Completed
47 enrolled 36 charts
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Osteosarcoma, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡